Answers are grounded in this paper and cite their sources.
BACKGROUND: Sepsis imposes a substantial clinical and economic burden, yet detailed patient-level data on long-term healthcare costs and quality of life (QoL) is mainly based on intensive care unit (ICU) survivors and relies on model-based projections for patients treated in general wards. AIM: To assess direct and indirect healthcare costs and QoL during the first year after community-onset sepsis. METHODS: Data were obtained from a cluster-randomized trial of patients hospitalized with sepsis of urological, abdominal or unknown origin in the Netherlands. Mean direct hospitalization costs were collected from hospital data. Additional healthcare utilization and productivity losses were obtained through structured questionnaires in a subset of patients followed for 12 months. We used inverse probability weighting to adjust for differences between the subset and full cohort. QALYs were estimated using the EQ-5D-5L at months 0 (then-test), 2, 6, and 12, and the SF-36 was administered at 12 months. RESULTS: Among 472 patients, 91 (19%) required ICU admission. Mean direct hospitalization costs were €8858 (95% CI: 7988-9855) per patient: €6697 (95% CI: 6185-7251) for general ward-admitted patients and €18,155 (95% CI: 14,856-22,342) for ICU-admitted patients. Over 12 months, mean total costs per patient were €30,889 (95% CI: 22,485-43,105): €25,839 (95% CI: 19,089-35,845) for general ward-admitted patients and €41,769 (95% CI: 23,132-48,943) for ICU-admitted patients. The weighted mean QALY during follow-up was 0.62 (95% CI: 0.51-0.74) compared with 0.65 (95% CI: 0.54-0.75) before sepsis. SF-36 at 12 months showed the greatest limitations in general health, physical role functioning, and energy/fatigue. CONCLUSION: Sepsis is followed by substantial healthcare and societal costs during the first year after admission, with a significant burden among patient treated in general wards. By providing Dutch patient-level cost and QoL data across ICU and non-ICU settings, this study enables improved economic evaluations and better-informed health policy. TRIAL REGISTRATION: European Union Clinical Trials Register (2021-001,840-83). Count = 296.
No takes yet. Share an insight, caveat, or question.
Koekenbier et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: